How the protein MIF affects retinal health and vision
Characterization of the role of MIF on retinal health and disease
Looking at whether blocking a protein called MIF can protect retinal cells and help prevent vision loss in people with ischemic and inflammatory retinal conditions like diabetic retinopathy and sickle cell retinopathy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11158654 on NIH RePORTER |
What this research studies
We aim to understand how the protein MIF contributes to inflammation, scarring, and cell loss in the retina. In lab models the team blocks MIF genetically or with drugs and measures retinal cell survival after injuries that mimic low blood flow and excitotoxic damage. The researchers study retinal support cells called Müller glia/astrocytes and analyze human genetic links between MIF variants and epiretinal membrane formation using patient samples. Results will help decide whether MIF-blocking drugs — some already tested for other diseases — could be repurposed to protect vision.
Who could benefit from this research
Good fit: Ideal candidates would include people with ischemic or inflammatory retinal conditions such as diabetic retinopathy, retinopathy of prematurity (for infant-focused components via collaborators), sickle cell retinopathy, or those with epiretinal membranes.
Not a fit: People whose vision loss is caused by non-inflammatory mechanisms or who already have advanced, irreversible retinal damage may not benefit from MIF-targeted approaches.
Why it matters
Potential benefit: If successful, this work could point to new treatments that reduce retinal inflammation, prevent scarring and photoreceptor loss, and help preserve or save vision.
How similar studies have performed: Preclinical animal and cell models have shown that blocking MIF can protect retinal neurons, and MIF inhibitors are being tested for other systemic diseases, but applying these approaches to human retinal disease is relatively new.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Cebulla, Colleen Marie — Ohio State University
- Study coordinator: Cebulla, Colleen Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.